In the Investment round of 2023, Dr. Nathalie Bravenboer has been awarded the AMS – VUmc investment grant to purchase a Complete Organ-on-Chip platform (€35.750). The Organ-on-Chip technology is a rapidly growing field that has the potential to revolutionize research and the development of treatments for diseases.
Some AMS researchers have already made a start with using Organ-on-Chip technology at a limited level, with equipment specifically designed for their tissue or porpoise. With this general Organ-on-Chip platform, new research groups can join this revolutionary way of investigating disease mechanisms and personalised treatment options at the cell or tissue level. The platform will also enable new research collaborations, such as the recently started VUTURE consortium on humanised tissue model to investigate fracture healing and bone regeneration. The general usability of the Organ-on-Chip platform makes this technology available for multiple AMS researchers to investigate a diversity of tissues e.g. bone, tendon, muscle, skin and cartilage.
The Organ–on-Chip platform enables research on individualised treatment when using patient derived tissues. Regulation for the registration of novel medications is rapidly changing, giving this the unique opportunity to completely replace animal experiments in the future. This is one of the key objectives of the Amsterdam UMC.